Philip Home

530 total citations
23 papers, 359 citations indexed

About

Philip Home is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Philip Home has authored 23 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Philip Home's work include Diabetes Management and Research (16 papers), Diabetes Treatment and Management (12 papers) and Metabolism, Diabetes, and Cancer (6 papers). Philip Home is often cited by papers focused on Diabetes Management and Research (16 papers), Diabetes Treatment and Management (12 papers) and Metabolism, Diabetes, and Cancer (6 papers). Philip Home collaborates with scholars based in United Kingdom, United States and Italy. Philip Home's co-authors include Yolanta T. Kruszynska, Neil McIntyre, K. G. M. M. Alberti, Richard M. Bergenstal, Maria Rojeski, Matthew C. Riddle, Geremia B. Bolli, M. Ziemen, Lawrence Blonde and Alka Shaunik and has published in prestigious journals such as Hepatology, Diabetes Care and Diabetes.

In The Last Decade

Philip Home

21 papers receiving 348 citations

Peers

Countries citing papers authored by Philip Home

Since Specialization

Citations

This map shows the geographic impact of Philip Home's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Home with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Home more than expected).

Fields of papers citing papers by Philip Home

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Home. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Home. The network helps show where Philip Home may publish in the future.

Co-authorship network of co-authors of Philip Home

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Home. A scholar is included among the top collaborators of Philip Home based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Home. Philip Home is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes 2025 ·Diabetes Care ·Geremia B. Bolli, Philip Home, Francesca Porcellati, Matthew C. Riddle, Hertzel C. Gerstein, Paola Lucidi, Carmine G. Fanelli, David R. Owens	3
2	An overview of insulin therapy for the non‐specialist 2025 ·Diabetes Obesity and Metabolism ·Philip Home	2
3	Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta‐analysis of non‐Asian studies 2025 ·Diabetes Obesity and Metabolism ·Philip Home, (unknown), (unknown), (unknown), Khadija Hafidh, Roopa Mehta, (unknown), İnan Anaforoğlu, Paul Serafini, (unknown)	0
4	The path for medical associations to sponsor trustworthy guidelines: is it feasible? 2022 ·Journal of the Royal Society of Medicine ·Duilio Pagano, Philip Home, Alar Irs, Jonathan A. Ledermann, Giuseppe Curigliano, (unknown), John Mandrola, Nick Freemantle	4
5	Efficacy and safety of iGlarLixi versus IDegAsp : Results of a systematic literature review and indirect treatment comparison 2021 ·Diabetes Obesity and Metabolism ·Philip Home, Roopa Mehta, Khadija Hafidh, (unknown), (unknown), Paul Serafini, (unknown)	7
6	Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis 2020 ·Diabetes Obesity and Metabolism ·Philip Home, Lawrence Blonde, Sanjay Kalra, Linong Ji, Patricia Guyot, (unknown), (unknown), Roshan P. Shah, (unknown), Alka Shaunik	16
7	Tackling obesity during the COVID‐19 pandemic 2020 ·Diabetes/Metabolism Research and Reviews ·Amit Akirov, Avivit Cahn, Stefano Del Prato, Philip Home, Luc Van Gaal, Juliana C.N. Chan, (unknown), Itamar Raz	3
8	Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison 2020 ·Diabetes Obesity and Metabolism ·Philip Home, Vanita R. Aroda, Lawrence Blonde, Patricia Guyot, Alka Shaunik, Mir Sohail Fazeli, (unknown), Sanjay Kalra, (unknown)	11
9	Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground 2019 ·Diabetes Care ·Philip Home	8
10	Cardiovascular outcome trials of glucose-lowering medications: an update 2019 ·Diabetologia ·Philip Home	58
11	Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open‐label clinical trial 2018 ·Diabetes Obesity and Metabolism ·Priscilla Hollander, (unknown), Raymond L. H. Lam, Gregory T. Golm, Roy Eldor, Michael F. Crutchlow, (unknown), Marc Rendell, Philip Home, Baptist Gallwitz, Julio Rosenstock	10
12	Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open‐label clinical trial 2018 ·Diabetes Obesity and Metabolism ·Philip Home, Raymond L. H. Lam, (unknown), Gregory T. Golm, Roy Eldor, Michael F. Crutchlow, (unknown), Julio Rosenstock, Priscilla Hollander, Baptist Gallwitz	5
13	Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes ( EDITION 4) 2017 ·Diabetes Obesity and Metabolism ·Philip Home, Richard M. Bergenstal, Geremia B. Bolli, M. Ziemen, Maria Rojeski, (unknown), Matthew C. Riddle	33
14	Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study 2017 ·Diabetes Obesity and Metabolism ·Philip Home, (unknown), Lawrence Blonde, Valérie Pilorget, Joseph Berlingieri, Nick Freemantle	3
15	Cardiovascular (CV) Risk Evaluation in People with Type 2 Diabetes (T2D) on Insulin Therapy (CREDIT) Study-CV Disease and CV Risk at Baseline 2009 ·UCL Discovery (University College London) ·Nick Freemantle, Beverley Balkau, N Danchin, (unknown), Michel Marre, Philip Home, Lawrence Blonde	1
16	Cardiovascular Risk Evaluation in People with Type 2 Diabetes (T2D) on Insulin Therapy (CREDIT) Study: Patterns of Initial Prescription of Insulin and Associated Changes in Oral Glucose-Lowering Drug (OGLD) Therapy 2009 ·UCL Discovery (University College London) ·Michel Marre, N Danchin, Nick Freemantle, Beverley Balkau, (unknown), Lawrence Blonde, Philip Home	2
17	Diabetes information systems: a key to improving the quality of diabetes care. 1996 ·PubMed ·(unknown), O M Gibby, Michael Hall, Philip Home, (unknown), (unknown), Douglas L. Rothman, N. D. Vaughan, Robert M. Williams, (unknown)	9
18	Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis 1991 ·Hepatology ·Yolanta T. Kruszynska, Philip Home, Neil McIntyre	111
19	Rotation of the anatomic regions used for insulin injections and day‐to‐day variability of plasma glucose in Type 1 diabetic subjects 1991 ·Practical Diabetes International ·John P. Bantle, MM Weber, Jonathan Thow, Philip Home	7
20	Observations on Blood Lipid and Intermediary Metabolite Concentrations During Conventional Insulin Treatment or CSII 1985 ·Diabetes ·P M Lawson, Philip Home, Richard M. Bergenstal, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact